by Sheila Isanaka, Ousmane Guindo, Celine Langendorf et al.
N Engl J Med 2017; 376:1121-1130, March 23, 2017
10 pp. 302 kB
Each year, rotavirus gastroenteritis is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in sub-Saharan Africa. The authors conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV, Serum Institute of India) to prevent severe rotavirus gastroenteritis. They conclude that three doses of BRV-PV, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in Niger.